The ethics of early stopping rules: Who is protecting whom?

被引：43

作者：

Cannistra, SA ^{[1
]}

机构：

[1] Beth Israel Deaconess Med Ctr, Program Gynecol Med Oncol, Boston, MA 02215 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 09期

关键词：

D O I：

10.1200/JCO.2004.02.150

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1542 / 1545

页数：4

共 8 条

[1] A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer [J].

Goss, PE ;

Ingle, JN ;

Martino, S ;

Robert, NJ ;

Muss, HB ;

Piccart, MJ ;

Castiglione, M ;

Tu, D ;

Shepherd, LE ;

Pritchard, KI ;

Livingston, RB ;

Davidson, NE ;

Norton, L ;

Perez, EA ;

Abrams, JS ;

Therasse, P ;

Palmer, MJ ;

Pater, JL .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (19) :1793-1802

[2] Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group trial [J].

Markman, M ;

Liu, PY ;

Wilczynski, S ;

Monk, B ;

Copeland, LJ ;

Alvarez, RD ;

Jiang, C ;

Alberts, D .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2460-2465

[3] Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study [J].

Muggia, FM ;

Braly, PS ;

Brady, MF ;

Sutton, G ;

Niemann, TH ;

Lentz, SL ;

Alvarez, RD ;

Kucera, PR ;

Small, JM .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (01) :106-115

[4] INTERRUPTED VERSUS CONTINUOUS CHEMOTHERAPY IN PATIENTS WITH METASTATIC BREAST-CANCER [J].

MUSS, HB ;

CASE, LD ;

RICHARDS, F ;

WHITE, DR ;

COOPER, R ;

CRUZ, JM ;

POWELL, BL ;

SPURR, CL ;

CAPIZZI, RL .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (19) :1342-1348

[5] Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup study [J].

Omura, GA ;

Brady, MF ;

Look, KY ;

Averette, HE ;

Delmore, JE ;

Long, HJ ;

Wadler, S ;

Spiegel, G ;

Arbuck, SG .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (15) :2843-2848

[6] Maintenance therapy in advanced ovarian cancer: Progression-free survival and clinical benefit [J].

Ozols, RF .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2451-2453

[7] Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: An intergroup trial (E1193) [J].

Sledge, GW ;

Neuberg, D ;

Bernardo, P ;

Ingle, JN ;

Martino, S ;

Rowinsky, EK ;

Wood, WC .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) :588-592

[8] Maybe more is better [J].

Thigpen, T .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (13) :2454-2456

← 1 →